Patricia Anne Ganz MD

Professor of Medicine, UCLA

10833 LeConte Ave., A2-125 CHSLos Angeles, CA 90095
Phone+1 310-206-1404
Fax+1 310-206-1404

Dr. Ganz is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ganz's full profile Already have an account?

Summary

I am a medical oncologist and Distinguished Professor of Health Policy & Management AND Medicine at the UCLA Schools of Public Health and Medicine. I am also the Associate Director for Population Science at the UCLA Jonsson Comprehensive Cancer Center. I was elected to the Institute of Medicine (IOM) in 2007, now National Academy of Medicine (NAM). I also served on the National Cancer Institute Board of Scientific Advisors from 2002-2007 and on the American Society of Clinical Oncology (ASCO) Board of Directors from 2003-2006. I received the American Cancer Society Medal of Honor in 2010. In my research I have pioneered the assessment of quality of life in cancer patients, and have focused much of my clinical and research efforts in the areas of breast cancer and its prevention. My major areas of research include cancer survivorship and the late effects of cancer treatment, measurement of patient reported outcomes in clinical treatment trials, and quality of care for cancer patients.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Gastroenterology, 2021 - 2027
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1976 - 1978
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1973 - 1976
David Geffen School of Medicine at UCLAClass of 1973

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1974 - 2028
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
America's Top Doctors Castle Connolly, 2002-2014

Clinical Trials

SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease
COMPLETED
SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial
COMPLETED
Letrozole in Preventing Breast Cancer in Postmenopausal Women
COMPLETED
PHASE2

Publications & Presentations

PubMed

COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Ca...
Caio Max Sao Pedro Rocha Lima, Greg Yothers, Thomas J George, Howard S Hochster, Hanna K Sanoff
Journal of Clinical Oncology. 2026-07-29
Are age and sex associated with variation in use of follow-up care and financial barriers to care in U.S. cancer survivors?
Gracie E Himmelstein, Patricia A Ganz
Journal of Cancer Survivorship. 2026-07-17
Social wellbeing, loneliness, and symptom burden in head and neck cancer survivors: a latent class analysis.
Eden R Brauer, Kristen R Choi, Laura Petersen, Patricia A Ganz, Maie A St John
Journal of Psychosocial Oncology. 2026-01-01

Journal Articles

Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study
Susan M Domchek, Wendy K Chung, Patricia A Ganz, Robert L Nussbaum, Journal of the National Cancer Institute
Reproductive and Gynecological Complication Risks Among Thyroid Cancer Survivors
Marcus Monroe, Patricia A Ganz, Journal of Cancer Survivorship
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk
Patricia A Ganz, Amanda E Toland, Susan M Domchek, Tanja Pejovic, Clinical Cancer Research

Lectures

Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breas...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Detecting Heart Issues in Breast Cancer SurvivorsNovember 5th, 2025
Identifying Cardiac Complications in Breast Cancer SurvivorsNovember 4th, 2025
Calculator May Predict Heart Risks After Breast CancerOctober 31st, 2025

Grant Support

Mindfulness Meditation for Younger Breast Cancer Survivors: Testing Digital Interventions in Clinical and Community SettingsUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
Cognitive Training for Cancer-related Cognitive Impairment: A Multi-Center Randomized Controlled TrialOHIO STATE UNIVERSITY2023–2028
Cognitive Training for Cancer-related Cognitive Impairment: A Multi-Center Randomized Controlled TrialOHIO STATE UNIVERSITY2023–2028
Advancing Analysis and Interpretation of Adverse Events and PROs in Cancer Clinical TrialsCEDARS-SINAI MEDICAL CENTER2023–2025
Advancing Analysis and Interpretation of Adverse Events and PROs in Cancer Clinical TrialsCEDARS-SINAI MEDICAL CENTER2023–2025